PL1, hope all is well. Here is some new information on a MS Biotech Research:
From RTTnews:
MediciNova Reports Positive Results For MN -166 In Two Year Phase II Clinical Trial In Patients With Multiple Sclerosis - Update [MNOV]
4/7/2008 7:46:32 AM San Diego, California - based biopharmaceutical company MediciNova Inc. (MNOV) announced positive clinical results for the two year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis. The trial reported slowing of disability progression and significant neuroprotective effects. Multiple sclerosis is an autoimmune condition in which the immune system attacks the central nervous system that leads to numerous physical and mental symptoms, and often progresses to physical and cognitive disability.
The company reported a significantly less sustained disability progression in patients who received MN-166 at either 30 mg or 60 mg per day for 24 months compared to those who have completed 12 months. Radiological measures corroborated the findings.
Further, the significant reduction in brain volume loss was observed in patients on 60 mg per day for 24 months compared to other treatment groups. Earlier, the company has noted that those on 60 mg per day of the compound for 12 months has less reduction in brain volume compared to placebo. The relative risk of neuronal loss that converts new inflammatory lesions identified at month two to persistent black holes were comparatively less in patients on 30 mg per day.
The orally administered compound was tried on a randomized, double blind, placebo controlled trial. The company said, MN-166 tolerated at all doses during the 24-month period. 297 patients were enrolled for the phase II trial and 245 patients completed the two-year term.
The company said its Scientific Advisory Board has recommended for advancing MN-166 into pivotal-design studies with clinical and MRI evaluations of Multiple Sclerosis progression as the primary objective.
The company announced the outcome of the first year Phase 1 trial results earlier in March 2007. However, the year one study has failed to significantly reduce cumulative brain lesion count on MRI, which was the protocol-defined primary endpoint of the study.
MNOV finished Friday's regular trading session at $4.00, up $0.40 on a volume of 1,10 shares.
TSURGE
INSANITY: Keep doing the same thing over and over hoping for a different outcome!!!
LifeFlight Helicopter landing on Scene after major crash
